Bhumbla Upasana, Shekhawat Laveena, Kothari Aditi, Rao Jatin
Assistant Professor, Geetanjali Medical College and Hospital, Udaipur, India.
PG Student, Department of Microbiology, Geetanjali Medical College and Hospital, Udaipur, India.
J Family Med Prim Care. 2020 Oct 30;9(10):5249-5251. doi: 10.4103/jfmpc.jfmpc_651_20. eCollection 2020 Oct.
Hepatitis C virus (HCV) has emerged as a leading cause of chronic hepatitis and hepatocellular carcinoma. Thus, this study was undertaken for detection and to observe genotypic distribution of the virus in this geographical region.
The aim of the study was to quantitatively detect HCV RNA in Hepatitis C patients and to determine the distribution pattern of its genotypes by real time polymerase chain reaction.
This is a retrospective study conducted in a tertiary care hospital. In seropositive Hepatitis C patients, quantification of HCV-RNA was done by real time PCR and in HCV-RNA positive samples, genotyping for HCV was conducted.
A total of 300 patients were recruited in the study, of which 165 were anti HCV positive and among them, 127 were HCV-RNA positive. These positive samples were further subjected to genotype determination using real time PCR. 98 samples were positive for genotype, where genotype 3 was seen in 90 patients, genotype 1, in 3 patients and genotype 4, in 5 patients.
Knowledge of genotype is crucial for management of HCV infection and prediction of prognosis. Patients infected with HCV genotype 1 and 4 will have to receive IFN and ribavirin for a period of 48 weeks and show a poor sustained viral response. On the contrary, patients infected with HCV genotype 2 and 3 are reported to have better response to therapy.
丙型肝炎病毒（HCV）已成为慢性肝炎和肝细胞癌的主要病因。因此，开展本研究以检测该病毒并观察其在该地理区域的基因型分布。
本研究的目的是定量检测丙型肝炎患者中的HCV RNA，并通过实时聚合酶链反应确定其基因型的分布模式。
这是一项在三级护理医院进行的回顾性研究。在血清学阳性的丙型肝炎患者中，通过实时PCR对HCV-RNA进行定量，并对HCV-RNA阳性样本进行HCV基因分型。
本研究共招募了300名患者，其中165名抗HCV阳性，其中127名HCV-RNA阳性。这些阳性样本进一步通过实时PCR进行基因型测定。98个样本基因型阳性，其中90名患者为基因型3，3名患者为基因型1，5名患者为基因型4。
了解基因型对于HCV感染的管理和预后预测至关重要。感染HCV基因型1和4的患者必须接受48周的干扰素和利巴韦林治疗，且持续病毒应答较差。相反，据报道感染HCV基因型2和3的患者对治疗反应较好。
